CRISPR-based diagnostics repurpose the immune machinery of bacteria into sequence-detecting instruments. Two Cas proteins dominate the field: Cas12, which targets DNA and underlies the DETECTR platform developed by Mammoth Biosciences, and Cas13, which targets RNA and powers the SHERLOCK platform associated with Sherlock Biosciences. The molecular trick in both systems is the same in principle: once the Cas protein finds its programmed sequence, it switches on a promiscuous cutting activity that shreds nearby reporter molecules, converting one binding event into a strongly amplified, measurable signal.
CRISPR Diagnostic Mechanisms: Cas12 vs. Cas13
Both platforms follow a shared three-stage logic, differing mainly in the nucleic acid they read and the collateral cleavage they unleash. The framework below traces that cause-and-effect chain for each system, from the moment the effector protein is aimed at a sample to the moment a signal becomes visible.
| Stage | Cas12 / DETECTR (DNA) | Cas13 / SHERLOCK (RNA) |
|---|---|---|
| 1. Target recognition | A guide RNA directs the Cas12 effector (variants such as Cas12a are commonly used) to a complementary DNA sequence in the sample. | A guide RNA directs the Cas13 effector (variants such as Cas13a are commonly used) to a complementary RNA sequence; this programmable RNA-guided ribonuclease belongs to the type VI CRISPR-Cas system. |
| 2. Collateral cleavage activated | Binding to the specific target DNA triggers non-specific single-stranded DNA cleavage activity in the activated Cas12 protein. | Binding to the specific target RNA triggers non-specific RNA cleavage activity in the activated Cas13 protein. |
| 3. Signal generation | Nearby ssDNA reporter molecules are degraded, producing a detectable signal. | Nearby RNA reporter molecules are degraded, producing a detectable signal. |
The key amplification insight is that a single recognition event can license the destruction of many reporters. That is what makes these assays sensitive enough to interest developers of accurate, fast, and scalable testing solutions, a goal the biomedical literature explicitly links to the surge of Cas12 and Cas13 research since 2019. The exact reporter molecules and signal formats vary from assay to assay, but the cause-and-effect chain holds across platforms.
Cas12-based DETECTR: Mechanism for DNA Detection
DETECTR's foundation is the Cas12 protein, which searches for DNA rather than RNA. The diagnostic process begins when a guide RNA pairs the Cas12 effector with a matching DNA sequence, a step the biomedical literature describes as the CRISPR-Cas system recognizing specific nucleic acid sequences through its enzymology combined with an amplification process. Researchers commonly work with specific Cas12 variants such as Cas12a for this purpose.
The decisive moment comes after recognition. Reviews of the CRISPR-Cas system report that activated Cas12 exhibits non-specific single-stranded DNA cleavage activity, triggered upon binding to its specific DNA target. In a diagnostic assay, that activity is pointed at reporter molecules: as the activated enzyme cuts any ssDNA reporters in its vicinity, it converts the molecular question of whether a given DNA sequence is present into an observable output.
This collateral behavior is the engineering insight. Cas12 is not precise once activated; it cleaves indiscriminately. That imprecision, which would be a liability in genome editing, is exactly what a diagnostic needs, because each bound target drives many reporter-cleavage events and therefore an amplified signal. The literature notes that publications on CRISPR/Cas12 increased several-fold since 2019, reflecting the development of testing solutions built on this chemistry.
Because Cas12 reads DNA directly, it is naturally suited to analytes whose genomic material is DNA, including bacterial pathogens and DNA viruses. The same literature ties Cas12-based diagnostics to demonstrated infectious disease detection of HPV, alongside multiplexed diagnostic targets including influenza, HIV, and SARS-CoV-2, and to cancer applications.
Cas13-based SHERLOCK: Mechanism for RNA Detection
SHERLOCK works from the RNA side of the ledger. Cas13 is a programmable single-effector RNA-guided ribonuclease in the type VI CRISPR-Cas system, capable of targeting a wide range of single-stranded RNA viruses. In 2018, Gootenberg and colleagues developed the SHERLOCK platform, described in the literature as "Specific Highly Sensitive Enzyme Report Unlocking," which detected individual molecules of RNA or DNA through isothermal pre-amplification combined with Cas13.
Mechanistically, the Cas13-guide RNA complex first recognizes a complementary RNA sequence in the sample. That binding event activates Cas13's collateral RNA cleavage activity, which then degrades nearby RNA reporters. As with Cas12, the reporter molecules are chosen so their cleavage releases a measurable signal, and one activated enzyme can process many reporters, which is how the platform reaches single-molecule sensitivity when paired with pre-amplification.
The practical consequence of Cas13's RNA targeting is direct detection of viral genomes and other RNA analytes without a separate DNA intermediate. A related Cas13 system, CARVER (Cas13-assisted virus expression and readout restriction), has likewise been proposed for rapid diagnosis of emerging infectious diseases and antiviral drug development, illustrating how the same collateral-cleavage chemistry extends beyond diagnostics into therapeutic research.
Reported application areas for Cas13-based detection include Zika and Dengue virus, both RNA viruses, consistent with the protein's natural RNA targeting. The breadth of these targets reflects the programmability of the guide RNA: changing the sequence the guide matches redirects the entire detection apparatus to a new pathogen or variant.
Comparing SHERLOCK and DETECTR Platforms
| Attribute | DETECTR | SHERLOCK |
|---|---|---|
| Core protein | Cas12 (Cas12a variants commonly used) | Cas13 (Cas13a variants commonly used) |
| Target nucleic acid | DNA | RNA |
| Collateral cleavage | Non-specific ssDNA cleavage | Non-specific RNA cleavage |
| Company behind the platform | Mammoth Biosciences | Sherlock Biosciences |
The comparison is ultimately a question of analytical fit: a DNA pathogen or genetic variant points toward a Cas12-based approach, while an RNA virus points toward Cas13. Both platforms share the same amplification logic, so the choice between them is driven less by sensitivity architecture than by the chemistry of the target molecule itself.
The scientific literature documents surging publication activity on both Cas12 and Cas13, driven by applications in infectious disease detection such as Zika, Dengue, and HPV, multiplexed diagnostics including influenza, HIV, and SARS-CoV-2, and cancer. The same review literature extends the potential scope to genetic disorders, positioning CRISPR diagnostics as tools whose target list is still expanding rather than fixed.
Two boundaries are worth stating plainly. This article explains mechanisms; it is not a guide for performing these tests, and it does not evaluate the clinical performance or regulatory approval status of specific commercial diagnostic products. Nor does it attempt an exhaustive catalogue of every disease CRISPR tools can detect; the examples above are those documented in the retained biomedical literature.
Implications for Disease Detection and Research
Healthcare professionals, biotech investors, and researchers should recognize CRISPR-based diagnostics as a rapidly evolving field offering precise and adaptable tools for nucleic acid detection. The core value proposition rests on two properties visible in the mechanism itself: programmability, since a guide RNA swap retargets the assay, and built-in signal amplification, since collateral cleavage multiplies a single binding event into many reporter cuts.
For clinicians, the practical relevance is the field's movement toward rapid, sensitive detection of infectious agents and, prospectively, genetic disorders and cancer markers. For researchers, the Cas12/Cas13 split defines two distinct toolkits depending on whether the analyte is DNA or RNA. For investors, the landscape is concentrated around two named platforms, DETECTR at Mammoth Biosciences and SHERLOCK at Sherlock Biosciences, with publication growth on both proteins since 2019 indicating sustained development activity.
The field's trajectory is legible in its literature: publication growth on Cas12 and Cas13, platform development by the two companies, and expanding target lists spanning infectious disease, multiplexed panels, and cancer. A concrete way to track maturity is to monitor new research publications and regulatory approvals for expanded applications and commercial availability of CRISPR diagnostic platforms, which will indicate whether these collateral-cleavage assays move from proof-of-concept breadth into routine clinical use.





